SMAD family member 6 (SMAD6)

SMAD family member 6 (SMAD6) is an intracellular signal transducer and transcriptional modulator that belongs to the SMAD family, which mediates and negatively regulates signals from the transforming growth factor-beta (TGF-β) and bone morphogenetic protein (BMP) superfamilies[1][3][4]. SMAD6 acts primarily as an inhibitor (“I-Smad”) of BMP signaling through competitive binding and by preventing the formation of transcriptionally active SMAD complexes, thereby functioning as a critical brake in cellular differentiation, development, and immune modulation[2][3][4][5]. Loss-of-function variants in SMAD6 are associated with several congenital and disease phenotypes, such as craniosynostosis, cardiovascular malformations, and certain cancers; its activity is tightly regulated and integrated with multiple major signaling pathways, including Notch, Wnt, and inflammatory signaling cascades[3][5]. There are no drugs directly targeting SMAD6 clinically, but its modulatory role makes it a potential target for interventions in diseases of excessive BMP/TGF-β activity.

Other names

Mothers against decapentaplegic homolog 6MADH6MAD homolog 6mothers against DPP homolog 6SMAD 6hSMAD6HsT17432AOVD2MADH7

Intracellular inhibition of BMP and TGF-β signaling by competition with SMAD4 for receptor-activated SMAD binding, thereby preventing downstream gene transcription[2][4][7]. Promotion of E3 ubiquitin ligase-mediated degradation of target proteins in osteoblasts, limiting differentiation[3]. Suppression of pro-inflammatory signaling by interfering with NF-κB pathway components[4]. Recruitment of corepressors such as CtBP to gene promoter regions to repress BMP-induced transcription[3].